All companies › MEDP

MEDP · Medpace Holdings, Inc.

Everything on this page is public record — SEC Form 4 filings and congressional disclosures — alongside any INSIDER SCANNER research case for this company.

Open-market buys0
Open-market sells9
Research cases0
Last filing2026-09-30

Insider flow: Selling only — a count of disclosed transactions, not a rating or a recommendation.

Insider transaction timeline

Every reported transaction, positioned by trade date. Purchases sit above the axis, sales below; circle area is proportional to dollar value. No share-price line is drawn — this feed carries transaction prices only, and a price history inferred from them would imply market data the filings do not contain.

Open-market purchase Open-market sale
2026-09-17 — Troendle August J. · sold 10,880 @ $620.40 2026-09-21 — Troendle August J. · sold 21,883 @ $623.29 2026-09-22 — Troendle August J. · sold 49,018 @ $628.11 2026-09-23 — Troendle August J. · sold 16,083 @ $628.64 2026-09-24 — Troendle August J. · sold 27,833 @ $621.33 2026-09-25 — Troendle August J. · sold 154 @ $620.60 2026-09-28 — Troendle August J. · sold 2,410 @ $620.07 2026-09-29 — Troendle August J. · sold 26,701 @ $621.02 2026-09-30 — Troendle August J. · sold 21,966 @ $625.47
2026-09-172026-09-30

Insider participation

One row per insider, one cell per reported transaction, shaded by value. Repeat buying and activity clustered in time are visible at a glance.

Troendle August J. President & CEO, Director, 10% owner
Included with a free account

The analysis built on top of these filings

The filings above are public record and stay public here. What an account adds for $MEDP is the reading of them — and for this company, that is what the list below says it is, no more.

  • Transaction timelineThe [{'transaction_date': '2026-09-30', 'insider_name': 'Troendle August J.', 'insider_title': 'President & CEO, Director, 10% owner', 'transaction_type': 'Open-market sell', 'shares': 21966.0, 'price': 625.47, 'value': 13739074.02, 'is_buy': False}, {'transaction_date': '2026-09-29', 'insider_name': 'Troendle August J.', 'insider_title': 'President & CEO, Director, 10% owner', 'transaction_type': 'Open-market sell', 'shares': 26701.0, 'price': 621.02, 'value': 16581855.02, 'is_buy': False}, {'transaction_date': '2026-09-28', 'insider_name': 'Troendle August J.', 'insider_title': 'President & CEO, Director, 10% owner', 'transaction_type': 'Open-market sell', 'shares': 2410.0, 'price': 620.07, 'value': 1494368.7, 'is_buy': False}, {'transaction_date': '2026-09-25', 'insider_name': 'Troendle August J.', 'insider_title': 'President & CEO, Director, 10% owner', 'transaction_type': 'Open-market sell', 'shares': 154.0, 'price': 620.6, 'value': 95572.4, 'is_buy': False}, {'transaction_date': '2026-09-24', 'insider_name': 'Troendle August J.', 'insider_title': 'President & CEO, Director, 10% owner', 'transaction_type': 'Open-market sell', 'shares': 27833.0, 'price': 621.33, 'value': 17293477.89, 'is_buy': False}, {'transaction_date': '2026-09-23', 'insider_name': 'Troendle August J.', 'insider_title': 'President & CEO, Director, 10% owner', 'transaction_type': 'Open-market sell', 'shares': 16083.0, 'price': 628.64, 'value': 10110417.12, 'is_buy': False}, {'transaction_date': '2026-09-22', 'insider_name': 'Troendle August J.', 'insider_title': 'President & CEO, Director, 10% owner', 'transaction_type': 'Open-market sell', 'shares': 49018.0, 'price': 628.11, 'value': 30788695.98, 'is_buy': False}, {'transaction_date': '2026-09-21', 'insider_name': 'Troendle August J.', 'insider_title': 'President & CEO, Director, 10% owner', 'transaction_type': 'Open-market sell', 'shares': 21883.0, 'price': 623.29, 'value': 13639455.07, 'is_buy': False}, {'transaction_date': '2026-09-17', 'insider_name': 'Troendle August J.', 'insider_title': 'President & CEO, Director, 10% owner', 'transaction_type': 'Open-market sell', 'shares': 10880.0, 'price': 620.4, 'value': 6749952.0, 'is_buy': False}] reported transactions plotted over the window rather than listed, so concentration is visible.

Not available for MEDP today: no reported open-market purchases in this window, so there is no insider cost basis to compute; no research case — nothing here has cleared the scoring threshold. Both appear on this page on their own if that changes.

A free account opens all of it.

Not financial advice. This page reports public filings and past research output. It is not a recommendation to buy or sell, and no price target here is a prediction. Trade at your own risk.